Group items tagged

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

The Health and Social Care Secretary Steve Barclay has proposed a new £30 million fund to speed up the adoption of innovative medical technology in the NHS. He confirmed the plan today at the Conservative Party Conference 2023 in Manchester. Mr Barclay said that virtual wards will help healthcare professionals embrace new technology to improve patient care. He said: "It is vital that clinicians have access to the latest technology to save staff time, deliver high-quality care and help cut waiting lists - one of the government's top five priorities. "This investment will see the latest tech innovations rolled out across the NHS. From virtual ward beds to wearable medical devices, patients will be better supported, and we will ease pressures on hospitals this winter. "We're preparing for this winter earlier than ever before including delivering thousands more hospital beds and hundreds of new ambulances."

AmerisourceBergen, a leading pharmaceutical solutions organisation announced its intent to change its name to 'Cencora' to better reflect its bold vision and purpose-driven approach to creating healthier futures. Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen said: "Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care." AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023. The change to Cencora is aligned with the organisation's growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.

Charac, an NHS-integrated one-stop platform for independent community pharmacies, and Positive Solutions, the fastest growing pharmacy IT provider in the UK, have agreed on a collaboration to support community pharmacies through new integrated technology platform - MyHealthHub. The tech platform aims to give pharmacies a powerful and compelling tool to both help retain and attract new patients. The app will also allow the over 7,200 independent high street pharmacies which are lacking a digital footprint to compete with larger online pharmacies by providing them with an online presence. The long-term strategic partnership brings together Charac's innovative approach to patient relationship management and Positive Solutions trusted expertise in digital solutions for pharmacy. With Positive Solutions' Analyst PMR used daily by 16,000 pharmacy team members to process over 87 million scripts and 180 million items, the collaboration will help transform patient engagement and continue driving service business to pharmacies across the UK using a new innovative, integrative technology platform, MyHealthHub. MyHealthHub will not only integrate with Analyst PMR, but also forms part of an entire new technology ecosystem from Positive Solutions, the Hx platform and will be entirely interoperable.

Rosemont Pharmaceuticals (Rosemont) has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK. Through this acquisition Rosemont will expand its existing portfolio and have access to a pipeline of innovative products, providing lifesaving pharmaceuticals to the UK and overseas markets. Founded in 2012, Lucis has grown to become a leading provider in the development and licensing of novel and exclusive medicines. With over a dozen SKUs covering a variety of therapeutic areas, Lucis has established a strong portfolio that, in addition to a pipeline of innovative developments, serve the growing patient need for liquid medicines. The acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22. "As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets" said Howard Taylor, Chief Executive Officer of Rosemont.

The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for branded medicines pricing on Thursday (4 May). A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023 In their first meeting, the government, NHS England and industry - represented by the ABPI -expected to agree to a shared negotiation aim of working toward a mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth. Health Minister, Will Quince, said: "These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times - one of the Prime Minister's 5 priorities. The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life sciences sector.

The UK Department of Health and Social Care (DHSC) has signed a new US$10 million (7.8 million pounds) grant agreement with global non-profit organisation, FIND. This extends the UK government's support to FIND through the Global AMR Innovation Fund (GAMRIF) for another four years. FIND recently announced the GAMRIF funding, which will be used to support its three-pronged strategy to prevent AMR emergence and halt its development. Dr Cassandra Kelly-Cirino, Vice President, Health Programmes at FIND, said: "Lack of essential diagnostics that can be accessed by people when and where they are needed is jeopardizing global efforts to combat AMR everywhere. We are grateful to GAMRIF for the continued support as we work in partnership on this multi-faceted strategy to save lives."

The Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised an innovative and first-of-its-kind gene-editing treatment for sickle-cell disease and transfusion-dependent β-thalassemia. Known as Casgevy (exagamglogene autotemcel), the treatment is based on the innovative gene-editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020. Casgevy is the first medicine to be licensed that uses CRISPR, and it is to be used for treating patients aged 12 and over. To date, a bone marrow transplant has been the only permanent treatment option for these life-long conditions, which in some cases can be fatal. The MHRA's authorisation came after a rigorous assessment of its safety, quality and effectiveness.

The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and diagnostics. Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy. This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated. The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier and better diagnostic technologies, to medical devices. The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.

The National Health Services England (NHSE) is poised to revolutionise diabetes management with the introduction of the 'artificial pancreas', also known as the Hybrid Closed Loop system, to treat type 1 diabetes. This pioneering initiative, endorsed by the National Institute of Health Care and Excellence (NICE), represents a global first in healthcare innovation. With 269,095 individuals grappling with type 1 diabetes in England, the Hybrid Closed Loop system is set to cater to tens of thousands of children and adults across the nation. This cutting-edge device operates by seamlessly monitoring blood glucose levels and autonomously adjusting insulin dosage through a pump, by eliminating the need for regular insulin injections. Furthermore, it holds the promise of averting life-threatening hypoglycaemic and hyperglycaemia episodes, mitigating significant risks associated with the condition. To facilitate the identification of beneficiaries, NHSE has allocated a substantial sum of £2.5 million, ensuring that those who could benefit from this innovative solution receive the necessary support.

Explore the innovations in mental health care through our online cme live webinar. Intended for Psychiatrists, Psychologists, Primary Care physicians and nurses. where we explore the forefront of advanced therapies and integrative approaches in mental health treatment. This event, scheduled for May 09, 2024, brings together experts and pioneers in the field to share insights on groundbreaking strategies.

Large collection of healthcare innovations focused on AIDS and HIV.

The 2011 report presents expanded analyses of care received by older Americans. It also addresses six priority areas for quality improvement, as identified in the National Strategy for Quality Improvement in Health Care report and presents novel strategies for improving quality and reducing disparities from AHRQ's Health Care Innovations Exchange.

Published 25 February 2014 Cambridge Healthtech Associates (CHA) has announced a new program to accelerate innovation in life sciences and health care. Announcing the launch of the first-ever tool in life sciences and health care to evaluate and rank new technologies and services via an end-user process.

Save Local Now provide listings for Innovative Hospice Care services for terminally ill patients and their families in Belleville, IL 62220 area. They provide individualized, quality care every step of the way and deliver expert, personalized care with compassion and respect. These include pain management, ongoing clinical care, patient and family psychological support and spiritual counseling that can help terminally ill patients achieve comfort and peace.

Ochsner is led by the President and CEO, Warner Thomas - a leader with a strategic vision. He exemplifies courage in a time of change to ensure that the organization positively embraces disruption and continues to move in the right direction that is best for its patients.

McDonald's is the secondlargest fast-food restaurant chain in the world, available in 119 countries with approximately 36,900 restaurants and nearly 68 million customers visiting every day. Innovation has played a huge part in its success.

Today, pharmaceutical companies can't simply make an effective drug and count on healthcare providers (HCPs) to come to them - they have to find innovative ways to attract them. Statista shows that in 2015 there were only 3,286 pharma companies with active research and development pipelines. In 2023, this number jumped to more than 5,500. As an earth-shattering number of new drugs are flooding the market each year, HCPs are having a hard time determining the best medicine for their patients. Meanwhile, pharma companies invest more in marketing to help HCPs get rid of choice paralysis and make them choose their solution over that of competitors. In this article, we will share the tried-and-true tactics to build a strong pharma brand. Get creative with interactive email marketing One…two…three…No, we're not counting to run a marathon. Three seconds is what you've got to pull your reader in with your email. Fail to quickly grab the audience's attention? We've got some bad news for you. Nobody's going to bother reading about how amazing your pharmaceutical product is if you're churning out generic emails with artificial intelligence tools.

Bristol-based Titan PMR, a technology firm specialising in PMR systems for community pharmacies, is set to roll out an innovative platform named 'Titanverse,' that it claims will redefine pharmacy management, offering comprehensive solutions extending beyond prescription management. This new platform takes a versatile approach, efficiently managing all facets of pharmacy operations, from high-level management down to daily tasks, according to top company officials. "Our aim is to reshape pharmacies into genuine health hubs, providing advanced services and harnessing state-of-the-art technologies," said Tariq Muhammad, CEO of Titan PMR. "Titanverse, our latest offering, is positioned to ignite this transformation, revolutionising clinical services in the same way its predecessor revolutionised dispensing. With Titanverse, we have the vehicle to drive this vision forward, placing pharmacies at the forefront of primary care in the future." Titanverse adopts a Teams approach, catering to pharmacies with multiple locations or specific focuses. It furnishes real-time analytics and employs a color-coded rating system for swift performance evaluation. Moreover, the platform eases operations by enabling task delegation, encompassing clinical checks and dispensing, all while backing private services with adaptable templates and workflows.

Lo's Pharmacy, a Yorkshire-based pharmacy chain is adopting a new approach to hub and spoke in a first of a kind model to be used in the UK. The pharmacy will centralise its repeat prescription dispensing service for original packs with the support of its medication wholesaler. The independent group, which has 25 NHS community pharmacies across Yorkshire, will install Centred Solution's Automated FLOWRx Hub product at its central dispensing facility in Wath-Upon-Dearne, South Yorkshire. But unlike other FLOWRx customers, who pick packs from a robotic dispensing system or internal warehouse, Lo's Pharmacy will receive patient-specific flow totes directly from their wholesaler which can then be processed by their hub. This workflow has not been used anywhere else in the country until now and it is a revolutionary approach to hub and spoke dispensing, showing what can be achieved when key players decide to collaborate. It further demonstrates that there are range of variations of hub and spoke models available and accessible to independent and multiple community pharmacies across the UK.